1)両角國男:腎移植慢性拒絶反応の病態と治療―慢性移植腎機能障害(慢性拒絶反応)の病態.泌尿紀要48:673-677, 2002
2)Sofue T, et al:Pre-existing arteriosclerotic intimal thickening in living-donor kidneys reflects allograft function. Am J Nephrol 36:127-135, 2012
3)Meirer-Kriesche H, Kaplan B:Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes. A paired donor kidney analysis. TRANSPLANTATION 74:1377-1381, 2002
4)Miyazawa N, et al:Methylglyoxal augments intracellular oxidative stress in human aortic endothelial cells. Free Radical Res 44;101-107, 2010
5)河村 毅,他:pre-emptive腎移植の適応―生体腎移植と献腎移植の観点から.秋澤忠男(編):変革する透析医学,pp437-444,医薬ジャーナル社,2012
6)川西秀樹:on-line HDFは最良の治療手段か.秋澤忠男(編):変革する透析医学,pp76-82,医薬ジャーナル社,2012
7)Scribner BH, Oreopoulos DG:The hemodialysis product(HDP);A better index of dialysis adequacy than K+/V Dialysis Transplant 31:13-15, 2002
8)Pauly RP, et al:Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant 24:2915-2919, 2009
9)Pauly RP, et al;on behalf of the CAN-SLEEP Collaborative Group:Patient and technique survival among a Canadian multicenter nocturnal home hemodialysis cohort. Clin J Am Soc Nephrol 5:1815-1820, 2010. doi:10.2215/CJN.00300110
10)Barua M, et al:Successful pregnancies on nocturnal home hemodialysis. Clin J Am Soc Nephrol 3:392-396, 2008. doi:10.2215/CJN.04110907
11)Tennankore KK, et al:Intensive home haemodialysis;Benefits and barriers. Nature Reviews Nephrology, 24 July 2012. doi:10.1038/nrneph.2012.145.
12)政金生人:トロントの在宅血液透析.患者視点の新しい透析治療―わかりやすい計画から実際の処方まで,pp95-97新興医学出版社,2011
13)両角國男,他:腎臓内科医の期待する腎代替療法の在り方.秋澤忠男(編):変革する透析医学,pp429-436,医薬ジャーナル社,2012
14)Fadem SZ, et al:Satisfaction with renal replacement therapy and education;The American Association of Kidney Patients Survey. Clin J Am Soc Nephrol 6:605-612, 2011